Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Seralutinib - Gossamer Bio

Next Previous
Drug Profile

Seralutinib - Gossamer Bio

Alternative Names: GB-002; PK-10571

Latest Information Update: 01 Oct 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator YM BioSciences
  • Developer Gossamer Bio
  • Class Amides; Pyrazines; Pyridines; Small molecules
  • Mechanism of Action Macrophage colony-stimulating factor receptor antagonists; Platelet-derived growth factor alpha receptor antagonists; Platelet-derived growth factor beta receptor antagonists; Proto-oncogene protein c-kit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pulmonary arterial hypertension
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Pulmonary arterial hypertension
  • Phase III Pulmonary hypertension

Most Recent Events

  • 23 Sep 2026 Preregistration for Pulmonary arterial hypertension (Treatment-experienced) in USA (Inhalation)
  • 09 Sep 2026 Gossamer Bio terminates the phase II TORREY OLE trial for Pulmonary arterial hypertension in US, Australia, Belgium, Czech Republic, France, Germany, Spain and the UK (Inhalation, Powder), due to enrolment issues (NCT04816604)
  • 28 Jul 2026 Gossamer and Chiesi terminate their Collaboration and License Agreement for Seralutinib

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top